Anhui Anke Biotechnology (Group)
Hefei · Founded 1994
About Anhui Anke Biotechnology (Group)
Anhui Anke Biotechnology (Group) Co., Ltd. (安科生物) is one of the largest biopharmaceutical high-tech enterprises in China. Founded in 1994, Anhui Anke Biotechnology has been concentrating on the research and development of bio-technical pharmaceuticals such as cell engineering and gene engineering. It has taken more than 10 programs successively such as The National 863 Plan, The National Key Science and Technology and The National Key Torch Program, and number of national-level independently developed new drugs of the company is nearly ten. Among them the dominant products include recombinant human interferon A2B Anterfron and its series of preparations, recombinant human growth hormone Ansomone and anti-sperm antibody detection (MAR method) kit An Sibao which are in great demand nationwide and exported to more than ten countries and regions.
Company Facts
- Founded: 1994
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $10K – $50K
- Funding stage: IPO
- Last round: Series A (Jul 2005)
- Ticker: szse:300009
- Website: ankebio.com
- Phone: 400-889-9131
Industries & Categories
Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/anhui-anke-biotechnology-group-2421545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.